Literature DB >> 8151305

Sequence variation in the capsid protein genes of human papillomavirus type 16.

P Pushko1, T Sasagawa, J Cuzick, L Crawford.   

Abstract

We have cloned and sequenced the L1 and L2 genes from human papillomavirus type 16 (HPV16) DNA-containing cervical cytology samples collected from the U.K. and Trinidad. Samples containing high copy numbers of HPV16 DNA were selected as being likely to contain fully functional virus DNA molecules in an episomal state, rather than in an integrated and possibly altered state. In comparison with the previously published sequence of HPV16 isolated from an invasive cancer a variety of differences were detected in both L1 and L2. The pattern of changes appears to be different in samples from the two geographic regions. One of the differences (resulting in D at position 202 of the L1 protein) reported recently to be functionally important for virus particle assembly was found to occur in all the samples examined. Variations in L1 found within known immunoreactive regions or hydrophobic domains should be taken into account in design of prophylactic vaccines for HPV16 based on virus-like particles. All variations within L2 protein were found in hydrophilic domains in the carboxy-terminal half of L2. These positions were highly variable among other types of papillomavirus and are located outside the known L2 immunoreactive region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151305     DOI: 10.1099/0022-1317-75-4-911

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

Authors:  T Yamada; M M Manos; J Peto; C E Greer; N Munoz; F X Bosch; C M Wheeler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Intratype variation in 12 human papillomavirus types: a worldwide perspective.

Authors:  A C Stewart; A M Eriksson; M M Manos; N Muñoz; F X Bosch; J Peto; C M Wheeler
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization.

Authors:  C M Wheeler; T Yamada; A Hildesheim; S A Jenison
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

4.  Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.

Authors:  Rongcun Yang; Cosette M Wheeler; Xiaojiang Chen; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Diana V Pastrana; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.

Authors:  T Sasagawa; M Inoue; M Lehtinen; W Zhang; S E Gschmeissner; M A Hajibagheri; J Finch; L Crawford
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

6.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.

Authors:  S Y Chan; H Delius; A L Halpern; H U Bernard
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Sequence variation in the L1 gene of human papillomavirus type 16 from Africa.

Authors:  J E Ramesar; E P Rybicki; A L Williamson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Papillomavirus DNA complementation in vivo.

Authors:  Jiafen Hu; Nancy M Cladel; Lynn Budgeon; Karla K Balogh; Neil D Christensen
Journal:  Virus Res       Date:  2009-04-18       Impact factor: 3.303

9.  Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments.

Authors:  T Yamada; C M Wheeler; A L Halpern; A C Stewart; A Hildesheim; S A Jenison
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Evidence of recombination within human alpha-papillomavirus.

Authors:  Manuel Angulo; Antonio Carvajal-Rodríguez
Journal:  Virol J       Date:  2007-03-28       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.